Welcome to CDC Stacks | Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers’ Diarrhea1 - 37286 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers’ Diarrhea1
Filetype[PDF - 465.29 KB]


Details:
No Related Documents.
You May Also Like:
  1. Risk Factors for Gastrointestinal Tract Colonization with Extended-Spectrum β-Lactamase (ESBL)–Producing Escherichia coli and Klebsiella Species in Hospitalized Patients
    Personal Author:
    Han, Jennifer H.; Nachamkin, Irving; Zaoutis, Theoklis E.; Coffin, Susan E.; Linkin, Darren R.; Fishman, Neil O.; Weiner, Mark G.; Hu, Baofeng; Tolomeo, Pam; Lautenbach, Ebbing;
    Published:
    Oct 23 2012
    Source:
    Infect Control Hosp Epidemiol. 2012; 33(12):1242-1245.
    Description:
    We describe the prevalence of and risk factors for colonization with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella species (ESBL-EK) in hospitalized patients. The prevalence of colonization with ESBL-EK was 2.6%. Col...
    File Type:
    Filetype[PDF - 85.61 KB]
  2. Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission
    Personal Author:
    Harris, Anthony D.; McGregor, Jessina C.; Johnson, Judith A.; Strauss, Sandra M.; Moore, Anita C.; Standiford, Harold C.; Hebden, Joan N.; Morris, J. Glenn;
    Published:
    Aug 2007
    Source:
    Emerg Infect Dis. 13(8):1144-1149.
    Description:
    Extended-spectrum beta-lactamase (ESBL)-producing bacteria are emerging pathogens. To analyze risk factors for colonization with ESBL-producing bacteria at intensive care unit (ICU) admission, we conducted a prospective study of a 3.5-year cohort of ...
    File Type:
    Filetype[PDF - 166.96 KB]
  3. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
    Personal Author:
    Aminkeng, F; Ross, CJD; Rassekh, SR; Brunham, LR; Sistonen, J; Dube, M-P; Ibrahim, M; Nyambo, TB; Omar, SA; Froment, A; Bodo, J-M; Tishkoff, S; Carleton, BC; Hayden, MR;
    Corporate Author:
    The Canadian Pharmacogenomics Network for Drug Safety Consortium
    Published:
    Apr 16 2013
    Source:
    Pharmacogenomics J. 14(2):160-170.
    Description:
    There is established clinical evidence for differences in drug response, cure rates and survival outcomes between different ethnic populations, but the causes are poorly understood. Differences in frequencies of functional genetic variants in key dru...
    File Type:
    Filetype[PDF - 543.67 KB]
  4. Multidrug-Resistant Corynebacterium striatum Associated with Increased Use of Parenteral Antimicrobial Drugs
    Personal Author:
    Hahn, William O.; Werth, Brian J.; Butler-Wu, Susan M.; Rakita, Robert M.;
    Published:
    Nov 2016
    Source:
    Emerg Infect Dis. 22(11):1908-1914.
    File Type:
    Filetype[PDF - 2.32 MB]
  5. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    September 25, 2009
    Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(37):1042-3.
    Description:
    The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons aged 11-18 years and for persons aged 2-55 years at increased...
    Status:
    superseded
    File Type:
    Filetype[PDF - 1.49 MB]